Drugs that contain Golodirsen

1. Drug name - VYONDYS 53

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10227590 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9994851 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US9024007 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10968450 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

US10421966 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof
Jun, 2025

(2 years from now)

EP2206781A9 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP2206781B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Apr, 2022

(5 months ago)

EP1766010A1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430B1 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A2 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP1766010A4 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

EP2500430A3 SAREPTA THERAPS INC Antisense Oligonucleotides For Inducing Exon Skipping And Methods Of Use Thereof
Jun, 2025

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10266827 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

US10995337 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

USRE47691 SAREPTA THERAPS INC Antisense oligonucleotides for inducing exon skipping and methods of use thereof Jun, 2025

(2 years from now)

Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients having a confirmed mutation of the dmd gene that is amenable to exon 53 skipping

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.